Posted by Michael Wonder on 19 Feb 2024
Datopotamab deruxtecan biologics license application accepted in the US for patients with previously treated advanced non-squamous non-small cell lung cancer
19 February 2024 - Application based on results from the TROPION-Lung01 Phase 3 trial.
Daiichi Sankyo and AstraZeneca’s biologics license application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with locally advanced or metastatic non-squamous non-small-cell lung cancer who have received prior systemic therapy.
